The DOI matches its Crossref record; 134 of the 138 references it cites were found in a registry or an index.
Resolution of inflammation in inflammatory bowel disease
Open accessAbstract
Treatment of inflammatory bowel disease at present mainly targets mediators of inflammation to stop or suppress pro-inflammatory processes. Typical examples are steroids, suppression of T cells by thioguanine nucleotides, or antibodies against cytokines such as tumour necrosis factor, interleukin 12, or interleukin 23. In addition to suppression of inflammation, development of therapeutic strategies that support resolution of inflammation or that actively resolve inflammation might be desirable. Resolution of inflammation is now seen as an active process involving specific mediators (eg, lipid mediators or specific cytokines) that is mandatory to restore organ function and completely shut down inflammation. The molecular pathways involved in resolution of inflammation have been investigated in recent years and could be adopted in treatment strategies for inflammatory bowel disease. Among these approaches are anti-integrin strategies and means to produce or locally increase restitution or resolution factors, such as restoration of the activity of transforming growth factor-β by anti-SMAD7 antisense oligonucleotides. The potential role of inflammation-resolving lipid mediators (eg, resolvins), however, still warrants further study and clinical development. This Review focuses on the specific role of active resolution of inflammation in inflammatory bowel disease pathophysiology. Potential therapeutic targets based on these pathways are also discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Together with prostaglandins and interferons, TNF-α is an important mediator of local and systemic inflammation and increases cause the cardinal clinical signs of inflammation, including heat, swelling, pain, and redness (66, 67).”
From Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders (2018) · cites this paper as [67]
Citations
Cites
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309990 · Cited by 2,302
Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome
Chassaing, B., Koren, O., Goodrich, J. K., Poole, A. C., Srinivasan, S., Ley, R. E., & Gewirtz, A. T. (2015) · Nature · doi:10.1038/nature14232 · Cited by 2,055
How colonization by microbiota in early life shapes the immune system
Gensollen, T., Iyer, S. S., Kasper, D. L., & Blumberg, R. S. (2016) · Science · doi:10.1126/science.aad9378 · Cited by 2,044
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846
Lamas, B., Richard, M. L., Leducq, V., Pham, H.-P., Michel, M.-L., Da Costa, G., Bridonneau, C., Jegou, S., Hoffmann, T. W., Natividad, J. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4102 · Cited by 1,482
Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor
Glocker, E.-O., Kotlarz, D., Boztug, K., Gertz, E. M., Schäffer, A. A., Noyan, F., Perro, M., Diestelhorst, J., Allroth, A., Murugan, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907206 · Cited by 1,461
Fujiwara, N., & Kobayashi, K. (2005) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010054022024 · Cited by 1,420
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Cited by
Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders
Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00044 · Cited by 1,189
“Together with prostaglandins and interferons, TNF-α is an important mediator of local and systemic inflammation and increases cause the cardinal clinical signs of inflammation, including heat, swelling, pain, and redness (66, 67).”
BackgroundSelf-citationThe Influence of Gut Microbiota on Oxidative Stress and the Immune System
Kunst, C., Schmid, S., Michalski, M., Tümen, D., Buttenschön, J., Müller, M., & Gülow, K. (2023) · Biomedicines · doi:10.3390/biomedicines11051388 · Cited by 213
Keep calm: the intestinal barrier at the interface of peace and war
Thoo, L., Noti, M., & Krebs, P. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2086-z · Cited by 159
Bernardo, D., Marín, A. C., Fernández‐Tomé, S., Montalban‐Arques, A., Carrasco, A., Tristán, E., Moreno, L. O., Mora‐Gutiérrez, I., Díaz-Guerra, A., Caminero-Fernández, R., et al. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0030-7 · Cited by 160
The microbiota and the gut–liver axis in primary sclerosing cholangitis
Hov, J. R., & Karlsen, T. H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00690-y · Cited by 139
Metadata
- Authors
- Rogler, G.
- Affiliations
- University of Zurich (CH)
- Corresponding author
- Rogler, Gerhard
- ORCID
- Rogler, Gerhard
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 2
- Issue
- 7
- Pages
- 521-530
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W2606862276
- Cited by
- 79
- References
- 138
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 9 · 2023: 11 · 2022: 8 · 2021: 8 · 2020: 7 · 2019: 9 · 2018: 7
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 159 d)
- Locations
- The Lancet. Gastroenterology & hepatology (acceptedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Swiss National Science Foundation (3347CO-108792)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- inflammation resolution, inflammatory bowel disease, lipid mediators, resolvins, anti-integrin therapy, TGF-beta, anti-inflammatory therapy, therapeutic target
- MeSH terms
- Anti-Inflammatory Agents, Environment, Humans, Intestinal Mucosa, Intestines, Macrophages, Neutrophils, Risk Factors, Inflammatory Bowel Diseases, Epigenesis, Genetic, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resolution of inflammation in inflammatory bowel disease. https://app.cochat.ai/papers/10.1016/s2468-1253(17)30031-6
- The paper
- Rogler, G. (2017). Resolution of inflammation in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(17)30031-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.